Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:22:50.747Z.
Calculation as of: 2026-10-06T18:22:50.747Z.
Quote observation: 2026-10-06T18:19:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$264.52M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
Market Cap
$269.70M
PE Ratio
N/A
TTM Avg
175.46
3Y Avg
175.46
5Y Avg
175.46
Market Cap
$270.31M
PE Ratio
N/A
TTM Avg
39.79
3Y Avg
40.81
5Y Avg
32.75
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $272.46M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.52M | N/A | 15.73 | 15.73 | 15.86 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.74M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.70M | N/A | 175.46 | 175.46 | 175.46 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | 39.79 | 40.81 | 32.75 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.20M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $271.06M | N/A | 7.56 | 7.56 | 7.56 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.89M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $261.82M | N/A | 16.07 | 13.93 | 35.67 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
